Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Phase 1 Completed 26 enrolled Dana-Farber Cancer Institute Curis, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.

Timeline

Start: 2016-10
Primary completion: 2025-12
Completion: 2025-12

Publications

Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec;14(23):e71417. doi: 10.1002/cam4.71417.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fimepinostat	Small molecule	27.5 mg/m2	Oral
Subject	Fimepinostat	Small molecule	35 mg/m2	Oral
Subject	Fimepinostat	Small molecule	45 mg/m2	Oral

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Summary

Timeline

Publications

Drugs

Indications